Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter pylori Treatment: A Multicenter Real-World Observational Study.

Created on 23 Oct 2026

Authors

Hong Lin, Qiuzhao Chen, Xianxing Cheng, Huping Huang, Yanling Zeng, Yi Lin, Xueping Huang, Yufan Xiao

Published in

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology. Oct 07, 2026. Epub Oct 07, 2026.

Abstract

Minocycline is a semisynthetic tetracycline with potent antimicrobial activity against Helicobacter pylori (H. pylori) and favorable pharmacokinetic properties. Although minocycline-based bismuth quadruple therapy (BQT) has shown encouraging eradication rates in controlled studies, evidence from real-world practice remains limited. This study assessed the effectiveness, safety, and cost-effectiveness of minocycline-containing BQT in a real-world setting.
In this multicenter, real-world observational study conducted at 25 hospitals in Fujian Province, China, between January and March 2025, adults with confirmed H. pylori infection were treated with 1 of 3 14-day BQT regimens: PBAC (amoxicillin- clarithromycin), PBMC (minocycline-clarithromycin), or PBML (minocycline levofloxacin), each combined with esomeprazole and bismuth. The primary endpoint was H. pylori eradication confirmed by a 13C-urea breath test after treatment. Secondary endpoints included adverse events, treatment adherence, and cost-effectiveness.
Of the 347 enrolled patients (PBAC, n = 115; PBMC, n = 117; and PBML, n = 115), 330 completed treatment and follow-up and were included in the per-protocol (PP) analysis. In the intention-to-treat analysis, eradication rates were 77.4% (89/115), 85.5% (100/117), and 84.3% (97/115) in the PBAC, PBMC, and PBML groups, respectively (P = .217); corresponding PP eradication rates were 80.9% (89/110), 90.9% (100/110), and 88.2% (97/110) (P = .079). Minocycline-containing regimens achieved numerically higher eradication rates than the amoxicillin-containing regimen. Adverse events occurred in 32.7%, 20.9%, and 23.6% of patients in the PBAC, PBMC, and PBML groups, respectively, while treatment adherence exceeded 94% in all groups. Pharmacoeconomic analysis identified PBML as the most cost-effective regimen (5.38 Chinese Yuan [CNY] per 1% eradication), followed by PBAC (5.41 CNY per 1% eradication) and PBMC (6.06 CNY per 1% eradication).
Minocycline-containing BQT demonstrated good tolerability, favorable cost effectiveness, and numerically higher eradication rates in routine clinical practice. It may represent a practical alternative to conventional amoxicillin- or tetracycline-based regimens. Further randomized trials are needed to validate these findings.

PMID:
42909322
Bibliographic data and abstract were imported from PubMed on 23 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 22
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement